Karthik Devarajan

Karthik Devarajan, MD, MBA, serves as the Senior Medical Monitor and Clinical Director of the International Cessa Trial at Cristcot, currently in FDA Phase III, since 2023. Previous experience includes an Otolaryngology Resident at The University of Texas Medical Branch at Galveston (2017 - 2022) and a Research Resident at LSU Health Shreveport (2016 - 2017). Karthik also held various roles in research and consulting related to healthcare, surgery, and emergency medicine, contributing to projects at institutions such as Tufts Medical Center, Unitus Seed Fund, Cambridge Health Alliance, Johnson & Johnson, and Siemens Healthcare. Karthik holds an MD from Tufts University School of Medicine and an MBA from The Heller School for Social Policy and Management at Brandeis University, along with additional educational credentials in neuroscience, music, and chemistry from Vanderbilt University.